APM: aptorumgroup.com EV/EBITDA Multiple
The market value dynamics of Aptorum Group Limited (APM), which reached 0.00, are driven by colossal expenditures on multi-year trials and strict regulatory oversight. High research costs in the absence of current sales create negative leverage and increase the cost of pipeline development. The business relies on the creation of unique diagnostic systems and the treatment of rare diseases, targeting untapped niches in the Asian region.
Metric breakdowns and analytics for aptorumgroup.com (APM)
- stock price and consensus target price:
- market capitalization information:
- issuer book value statistics:
- debt and solvency information:
- financial results and valuation multiples details:
APM - Final Profit|Future Profit Aptorum Group Limited|APM - P/E Multiple|Future Price to Earnings Aptorum Group|APM - Price/Earnings to Growth Multiple|Enterprise Value to EBITDA Ratio APM|APM - Income before deduction of interest, taxes and amortization|Net earnings per share (EPS TTM) Aptorum Group|APM - Net earnings per share for the trailing year|Year-over-year earnings per share growth for the last twelve months aptorumgroup.com|APM - Earnings per share increase in current year|Net earnings per share growth forecast for next year Aptorum Group Limited
Fundamental valuation:Aptorum (APM)
EV/EBITDA measures the total enterprise value, including debt, relative to operating profit before taxes, allowing for the determination of an asset's real price without the influence of financing structure. For Aptorum Group Limited (APM), which invests in drug development in collaboration with Hong Kong universities, the company's current EV/EBITDA ratio serves as an indicator of the capitalization efficiency of its scientific partnerships and determines the fundamental attractiveness of the shares during periods of market volatility.
Competing companies
Haleon Group - Enterprise Value to EBITDA Ratio|Enterprise Value to Operating Income Before Depreciation Ratio KVUE (Kenvue Health)|Verona Pharma plc - EV/EBITDA Multiple|Business Value to Operating Income Before Depreciation MENS (jyongbio.com)|LGND: EV/EBITDA Multiple|Company Value to EBITDA Amneal Pharmaceuticals, Inc. (AMRX)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Perrigo Company|ALVO: Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple LQDA|EV/EBITDA Multiple glpg.com (GLPG)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization ANI Pharmaceuticals, Inc. ANIP|MNKD (MannKind Corp) - Company Value to Operating Income Before Depreciation Ratio|AMPH: Enterprise Value to EBITDA Ratio|Pacira Corp - Enterprise Value to Operating Income Before Depreciation Ratio|ARS Pharmaceuticals (SPRY) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA theravance.com (TBPH)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Aquestive Therapeutics, Inc.|SCPH: Business Value to Operating Income Before Depreciation|Enterprise Value to EBITDA Ratio TECX (Tectonic Therapeutic, Inc.)|EV/EBITDA Multiple Tonix Pharmaceuticals Holding (TNXP)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization China SXT Pharmaceuticals, Inc. SXTC|EPRX - Enterprise Value to EBITDA Ratio|BHST: Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation EXOZ (Invizyne Technologies)|ORMP: EV/EBITDA Multiple|Enterprise Value to EBITDA Multiple Entera Bio ENTX|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization MindWalk Holdings|ABVC: Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Cumberland Pharmaceuticals Inc. (CPIX)|QNTM - Company Value to EBITDA|FibroGen Corp - Enterprise Value to EBITDA Ratio|EV/EBITDA Multiple Telomir Pharmaceuticals Corp TELO|RANI - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to Operating Income Before Depreciation Ratio SNYR|RLYB (rallybio.com) - Enterprise Value to EBITDA Ratio|Lexaria Bioscience Corp. - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Pulmatrix Corp|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization PTHL|EV/EBITDA Multiple LYRA|Total Company Value to Operating Income Before Depreciation Ratio impactbiomedinc.com|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization TNF Pharmaceuticals, Inc. TNFA|YCBD - Enterprise Value to EBITDA Ratio|PainReform Limited - EV/EBITDA Multiple|Total Company Value to Operating Income Before Depreciation Ratio Altamira Therapeutics CYTO|LIPO (Lipella Pharmaceuticals) - Enterprise Value to EBITDA Ratio|OPTN: Enterprise Value to Operating Income Before Depreciation Ratio|PIRS (Pieris Pharmaceuticals, Inc.) - EV/EBITDA Multiple|Company Value to EBITDA Procaps Group PROC|EV/EBITDA Multiple PTPI|Qilian International Corp - Enterprise Value to Operating Income Before Depreciation|EV/EBITDA Multiple SLRN (Acelyrin, Inc.)|EV/EBITDA Multiple tffpharma.com TFFP
